MedPath

Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction

Phase 1
Completed
Conditions
Cerebral Infarction
Registration Number
NCT02378974
Lead Sponsor
CHABiotech CO., Ltd
Brief Summary

The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects

Detailed Description

Cohort 1 : Cordstem-ST cells or Placebo on day 0 Cohort 2: Cordstem-ST cells or Placebo on day 0 and day 7

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of TEAEs6 month

Number of treatment related-adverse events during the study period

Secondary Outcome Measures
NameTimeMethod
Improvement in clinical function as assessed by BI6 month

Barthel Index (BI) compared to baseline at 6 months

Improvement in clinical function as assessed by mRS6 month

Modified Rankin Score (mRS) compared to baseline at 6 months

Improvement in clinical function as assessed by Brain MRI tratogram6 month

Brain MRI tratogram compared to baseline at 6 months

Improvement in clinical function as assessed by NIHSS6 month

National Institute of Health Stroke Scale (NIHSS) compared to baseline at 6 months

Trial Locations

Locations (1)

CHA Bundang Medical Center

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

CHA Bundang Medical Center
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.